Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis
Cystic fibrosis is a genetic disease typically characterized by progressive lung damage and premature mortality. Pulmonary exacerbations, or flare-ups of the lung disease, often require hospitalization for intensive treatment. Approximately 25% of patients with cystic fibrosis do not recover their b...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00301/full |
| _version_ | 1818692384686342144 |
|---|---|
| author | Andre Schultz Andre Schultz Andre Schultz Julie A. Marsh Julie A. Marsh Benjamin R. Saville Benjamin R. Saville Richard Norman Peter G. Middleton Hugh W. Greville Matthew I. Bellgard Scott M. Berry Tom Snelling Tom Snelling Tom Snelling Tom Snelling |
| author_facet | Andre Schultz Andre Schultz Andre Schultz Julie A. Marsh Julie A. Marsh Benjamin R. Saville Benjamin R. Saville Richard Norman Peter G. Middleton Hugh W. Greville Matthew I. Bellgard Scott M. Berry Tom Snelling Tom Snelling Tom Snelling Tom Snelling |
| author_sort | Andre Schultz |
| collection | DOAJ |
| description | Cystic fibrosis is a genetic disease typically characterized by progressive lung damage and premature mortality. Pulmonary exacerbations, or flare-ups of the lung disease, often require hospitalization for intensive treatment. Approximately 25% of patients with cystic fibrosis do not recover their baseline lung function after pulmonary exacerbations. There is a relative paucity of evidence to inform treatment strategies for exacerbations. Compounding this lack of evidence, there are a large number of treatment options already as well as becoming available. This results in significant variability between medication regimens prescribed by different physicians, treatment centers and regions with potentially adverse impact to patients. The conventional strategy is to undertake essential randomized clinical trials to inform treatment decisions and improve outcomes for patients with exacerbations. However, over the past several decades, clinical trials have generally failed to provide information critical to improved treatment and management of exacerbations. Bayesian adaptive platform trials hold the promise of addressing clinical uncertainties and informing treatment. Using modeling and response adaptive randomization, they allow for the evaluation of multiple treatments across different management domains, and progressive improvement in patient outcomes throughout the course of the trial. Bayesian adaptive platform trials require substantial amounts of preparation. Basic preparation includes extensive stakeholder involvement including elicitation of consumer preferences and clinician understanding of the research topic, defining the research questions, determining the best outcome measures, delineating study sub-groups, in depth statistical modeling, designing end-to-end digital solutions seamlessly supporting clinicians, researchers and patients, constructing randomisation algorithms and importantly, defining pre-determined intra-study end-points. This review will discuss the motivation and necessary steps required to embark on a Bayesian adaptive platform trial to optimize medication regimens for the treatment of pulmonary exacerbations of cystic fibrosis. |
| first_indexed | 2024-12-17T12:56:56Z |
| format | Article |
| id | doaj.art-9a4376be32994aa3ac3fc809dad1f799 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-17T12:56:56Z |
| publishDate | 2019-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-9a4376be32994aa3ac3fc809dad1f7992022-12-21T21:47:28ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-03-011010.3389/fphar.2019.00301427302Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic FibrosisAndre Schultz0Andre Schultz1Andre Schultz2Julie A. Marsh3Julie A. Marsh4Benjamin R. Saville5Benjamin R. Saville6Richard Norman7Peter G. Middleton8Hugh W. Greville9Matthew I. Bellgard10Scott M. Berry11Tom Snelling12Tom Snelling13Tom Snelling14Tom Snelling15Faculty of Health and Medical Sciences, The University of Western Australia, Crawley, WA, AustraliaDepartment of Respiratory Medicine, Perth Children’s Hospital, Nedlands, WA, AustraliaWesfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Nedlands, WA, AustraliaWesfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Nedlands, WA, AustraliaSchool of Population and Global Health, The University of Western Australia, Nedlands, WA, AustraliaBerry Consultants, Austin, TX, United StatesDepartment of Biostatistics, Vanderbilt University, Nashville, TN, United StatesSchool of Public Health, Curtin University, Bentley, WA, AustraliaLudwig Engel Centre for Respiratory Research, Westmead Institute for Medical Research, Sydney, NSW, AustraliaDepartment of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia0eResearch Office, Queensland University of Technology, Brisbane, QLD, AustraliaBerry Consultants, Austin, TX, United StatesWesfarmers Centre of Vaccines & Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Nedlands, WA, AustraliaSchool of Public Health, Curtin University, Bentley, WA, Australia1Department of Infectious Diseases, Perth Children’s Hospital, Nedlands, WA, Australia2Menzies School of Health Research, Charles Darwin University, Darwin, NT, AustraliaCystic fibrosis is a genetic disease typically characterized by progressive lung damage and premature mortality. Pulmonary exacerbations, or flare-ups of the lung disease, often require hospitalization for intensive treatment. Approximately 25% of patients with cystic fibrosis do not recover their baseline lung function after pulmonary exacerbations. There is a relative paucity of evidence to inform treatment strategies for exacerbations. Compounding this lack of evidence, there are a large number of treatment options already as well as becoming available. This results in significant variability between medication regimens prescribed by different physicians, treatment centers and regions with potentially adverse impact to patients. The conventional strategy is to undertake essential randomized clinical trials to inform treatment decisions and improve outcomes for patients with exacerbations. However, over the past several decades, clinical trials have generally failed to provide information critical to improved treatment and management of exacerbations. Bayesian adaptive platform trials hold the promise of addressing clinical uncertainties and informing treatment. Using modeling and response adaptive randomization, they allow for the evaluation of multiple treatments across different management domains, and progressive improvement in patient outcomes throughout the course of the trial. Bayesian adaptive platform trials require substantial amounts of preparation. Basic preparation includes extensive stakeholder involvement including elicitation of consumer preferences and clinician understanding of the research topic, defining the research questions, determining the best outcome measures, delineating study sub-groups, in depth statistical modeling, designing end-to-end digital solutions seamlessly supporting clinicians, researchers and patients, constructing randomisation algorithms and importantly, defining pre-determined intra-study end-points. This review will discuss the motivation and necessary steps required to embark on a Bayesian adaptive platform trial to optimize medication regimens for the treatment of pulmonary exacerbations of cystic fibrosis.https://www.frontiersin.org/article/10.3389/fphar.2019.00301/fulladaptive trialplatform trialBayesiancystic fibrosisexacerbationsmaster protocol |
| spellingShingle | Andre Schultz Andre Schultz Andre Schultz Julie A. Marsh Julie A. Marsh Benjamin R. Saville Benjamin R. Saville Richard Norman Peter G. Middleton Hugh W. Greville Matthew I. Bellgard Scott M. Berry Tom Snelling Tom Snelling Tom Snelling Tom Snelling Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis Frontiers in Pharmacology adaptive trial platform trial Bayesian cystic fibrosis exacerbations master protocol |
| title | Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis |
| title_full | Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis |
| title_fullStr | Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis |
| title_full_unstemmed | Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis |
| title_short | Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis |
| title_sort | trial refresh a case for an adaptive platform trial for pulmonary exacerbations of cystic fibrosis |
| topic | adaptive trial platform trial Bayesian cystic fibrosis exacerbations master protocol |
| url | https://www.frontiersin.org/article/10.3389/fphar.2019.00301/full |
| work_keys_str_mv | AT andreschultz trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT andreschultz trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT andreschultz trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT julieamarsh trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT julieamarsh trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT benjaminrsaville trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT benjaminrsaville trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT richardnorman trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT petergmiddleton trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT hughwgreville trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT matthewibellgard trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT scottmberry trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT tomsnelling trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT tomsnelling trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT tomsnelling trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis AT tomsnelling trialrefreshacaseforanadaptiveplatformtrialforpulmonaryexacerbationsofcysticfibrosis |